News Acquisitive Ipsen builds again with $952m Albireo buy French drugmaker Ipsen has continued a recent spate of deal-making with a $42-per-share offer to buy US biotech Albireo and its rare disease therapy Bylvay.
Views & Analysis Q&A: Albireo’s Ron Cooper on bile acid modulation While bile acids might not be as trendy as gene editing, modulating them has potential for first-in-class therapies for liver diseases.
News EU President fends off no-confidence vote over Pfizer texts EU President Ursula von der Leyen has survived a no-confidence vote over text messages she sent to Pfizer's CEO about COVID-19 vaccine procurement.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face